Cumberland Pharmaceuticals Inc.

250 articles with Cumberland Pharmaceuticals Inc.

• Cumberland Pharmaceuticals Reports 17% Revenue Growth for Full Year 2022

  3/7/2023

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company announced full year 2022 financial results and provided a Company update.

• Cumberland Pharmaceuticals to Announce Annual 2022 Financial Results

  2/28/2023

  Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

• Cumberland Pharmaceuticals Reports 41% Revenue Growth

  11/8/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period.

• Cumberland Pharmaceuticals Moves Into New Headquarters at Broadwest

  11/1/2022

  Cumberland Pharmaceuticals Inc. announced that it has moved its headquarters to the Broadwest campus in the Vanderbilt/West End corridor of Nashville.

• CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS

  11/1/2022

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022.

• Cumberland Pharmaceuticals Reports 14% Revenue Growth

  8/9/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period.

• CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021

  8/8/2022

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2021 Sustainability Report detailing its activities regarding its involvement in environmental, social and governance matters.

• CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

  8/2/2022

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.

• CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

  7/19/2022

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors.

• Cumberland Pharmaceuticals Reports 6% Revenue Growth

  5/10/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $11.2 million during the first quarter of 2022, - which is a 6% increase over the prior year period.

• Cumberland Pharmaceuticals To Announce First Quarter 2022 Financial Results

  5/3/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.

• Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

  3/31/2022

  Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc., headquartered in Nashville, and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East, headquartered in Riyadh, Saudi Arabia, announced the launch of Cumberland's Vibativ® injection in the Middle East.

• Cumberland Pharmaceuticals Reports 2021 Financial Results & Company Update

  3/8/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company announced full year 2021 financial results and provided a company update.

• Cumberland Pharmaceuticals To Announce Annual 2021 Financial Results

  3/1/2022

  Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022.

• CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA

  1/4/2022

  Cumberland Pharmaceuticals Inc. announced today that it has entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), from Kyowa Kirin, Inc.

• Caldolor® Now FDA Approved For Pre-Operative Administration

  11/29/2021

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.

• Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update

  11/9/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and third quarter 2021 financial results.

• Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results

  11/2/2021

  Cumberland Pharmaceuticals Inc. announced that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021.

• Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

  9/29/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the national launch of its RediTrex® line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.

• Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update

  8/10/2021

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, is providing a company update and second quarter 2021 financial results.